Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 2/20 | 0.58 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 4/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22649230 | 0.79 | KDM4E (0.56) | GRIN1GRIN2APKMKDM4EALDH1A1 | |
| SCHEMBL17298042 | 0.77 | GRIN1 (0.62) | GRIN1GRIN2APKMKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL636784 | 0.77 | TP53 (0.56) | GRIN1GRIN2APKMSMN1; SMN2MAPT | |
| SCHEMBL10966083 | 0.76 | KDM4E (0.62) | GRIN1GRIN2APKMKDM4EALDH1A1 | |
| SCHEMBL18160936 | 0.75 | GRIN1 (0.74) | GRIN1GRIN2APKMKDM4EALDH1A1 | |
| SCHEMBL19104677 | 0.73 | KDM4E (0.57) | GRIN1GRIN2APKMKDM4EALDH1A1 | |
| SCHEMBL20129431 | 0.73 | GRIN1 (1.00) | GRIN1GRIN2APKMKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL11061040 | 0.72 | ALDH1A1 (0.34) | PKMKDM4EALDH1A1HPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL636301 | 0.72 | MAPT (0.41) | GRIN1GRIN2APKMALDH1A1SMN1; SMN2 | |
| SCHEMBL1660663 | 0.72 | NPC1 (0.56) | GRIN1GRIN2APKMKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12071413-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-08-27 | — | — | US | disclosed |
| EP-3380970-B1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2023-01-04 | — | — | EP | disclosed |
| US-20220144784-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11155525-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200347022-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-11-05 | — | — | US | disclosed |
| US-10626096-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-04-21 | — | — | US | disclosed |
| US-20180282289-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12071413-B2 | Azole derivatives as apelin receptor agonist | APLNR, AGTR1, AGTR2 | GRIN1 1460/4885GRIN2A 3034/4885PKM 4002/4885 |
| US-11155525-B2 | Azole derivatives as apelin receptor agonist | APLNR, AGTR1, AGTR2 | GRIN1 1460/4885GRIN2A 3034/4885PKM 4002/4885 |
| US-20200347022-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | APLNR, AGTR1, AGTR2 | GRIN1 1606/4885GRIN2A 2862/4885PKM 4135/4885 |
| US-20220144784-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | APLNR, AGTR1, AGTR2 | GRIN1 1389/4885GRIN2A 2796/4885PKM 4216/4885 |
| US-20180282289-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | APLNR, AGTR1, AGTR2 | GRIN1 1375/4885GRIN2A 2787/4885PKM 4198/4885 |
| US-10626096-B2 | Azole derivatives as apelin receptor agonist | APLNR, AGTR1, AGTR2 | GRIN1 1461/4885GRIN2A 3042/4885PKM 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.